Payers Move to Pre-Authorize Expensive Genetic Tests

CEO Summary: Pre-authorization of expensive genetic and molecular tests is fast-becoming a priority for most of the nation’s health insurers. For clinical labs and pathology groups that don’t respond, this trend is a threat. On the other hand, because payers need all the skills and knowledge that labs possess to intelligently manage utilization of molecular …

Payers Move to Pre-Authorize Expensive Genetic Tests Read More »

To access this post, you must purchase The Dark Report.

Payers Move to Pre-Authorize Expensive Genetic Tests

Opportunity for labs to be paid on value and not as a commodity!

Comments

TABLE OF CONTENTS

Need A Group Membership? Company Discounts are Available!

You are reading premium content from The Dark Report, your primary resource for running an efficient and profitable laboratory.

Get Unlimited Access to The Dark Report absolutely FREE!

You have read 0 of 1 of your complimentary articles this month

You have read 0 of 1 of your complimentary articles this month